---
title: "KPTI.US (KPTI.US) — Related News"
type: "Symbol"
locale: "en"
url: "https://longbridge.com/en/quote/KPTI.US/news.md"
symbol: "KPTI.US"
name: "KPTI.US"
parent: "https://longbridge.com/en/quote/KPTI.US.md"
datetime: "2026-05-21T18:33:59.276Z"
locales:
  - [en](https://longbridge.com/en/quote/KPTI.US/news.md)
  - [zh-CN](https://longbridge.com/zh-CN/quote/KPTI.US/news.md)
  - [zh-HK](https://longbridge.com/zh-HK/quote/KPTI.US/news.md)
---

# KPTI.US (KPTI.US) — Related News

### [Karyopharm (KPTI) Leans on SENTRY in Pivotal Call](https://longbridge.com/en/news/287005767.md)
*2026-05-20T04:38:14.000Z*
> Karyopharm Therapeutics (KPTI) reported Q1 earnings, highlighting strong Phase III data from the SENTRY trial, which sho

### [12 Health Care Stocks Moving In Tuesday's Pre-Market Session](https://longbridge.com/en/news/286910054.md)
*2026-05-19T12:05:59.000Z*
> In Tuesday's pre-market session, MetaVia (MTVA) shares surged 50.5% to $1.67, while Virax Biolabs (VRAX) rose 38.68% to 

### [](https://longbridge.com/en/news/286592726.md)
*2026-05-15T15:52:15.000Z*
> Karyopharm Therapeutics shares are trading lower. The company reported its Q1 financial results.

### [RBC Capital Remains a Buy on Karyopharm Therapeutics (KPTI)](https://longbridge.com/en/news/286559865.md)
*2026-05-15T11:48:45.000Z*
> RBC Capital analyst Brian Abrahams maintained a Buy rating on Karyopharm Therapeutics (KPTI) with a price target of $16.

### [Karyopharm Therapeutics Inc. Stock 12‑Month Price Target Raised to $15, Implies 69% Upside](https://longbridge.com/en/news/286456766.md)
*2026-05-14T19:20:07.000Z*
> Karyopharm Therapeutics Inc.'s stock price target has been raised to $15, indicating a potential upside of 69%. This est

### [Karyopharm Therapeutics Inc. 1Q 2026: Revenue $35.1M, EPS $(1.24) — 10-Q Summary](https://longbridge.com/en/news/286411440.md)
*2026-05-14T11:51:00.000Z*
> Karyopharm Therapeutics Inc. reported Q1 2026 revenue of $35.1M, a 17% increase from Q1 2025, with a narrowed net loss o

### [Karyopharm Therap | 10-Q: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M](https://longbridge.com/en/news/286410631.md)
*2026-05-14T11:48:11.000Z*
### [Karyopharm Therap | 8-K: FY2026 Q1 Revenue Beats Estimate at USD 35.07 M](https://longbridge.com/en/news/286408783.md)
*2026-05-14T11:33:55.000Z*